Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. [electronic resource]
Producer: 20040408Description: 1071-7 p. digitalISSN:- 0732-183X
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Breast Neoplasms -- drug therapy
- Disease-Free Survival
- Docetaxel
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- In Situ Hybridization, Fluorescence
- Middle Aged
- Receptor, ErbB-2 -- antagonists & inhibitors
- Receptor, ErbB-3 -- antagonists & inhibitors
- Survival Analysis
- Taxoids -- administration & dosage
- Trastuzumab
- United States
- Up-Regulation
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.